Version history

{
  "session_id": "sess_sda-2026-04-12-ev-ad-biomarkers_20260412-082939",
  "round_number": 2,
  "agent_persona": "persona-skeptic",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "critique",
  "content": "\n\n# Skeptic's Evaluation of EV-Derived Biomarker Hypotheses for Early AD\n\n---\n\n## Hypothesis 1: NDEV p-tau231 as Ultra-Early Diagnostic Marker\n\n### Strongest Specific Weakness: Citation Misattribution and Mechanistic Imprecision\n\nThe hypothesis claims \"Winston et al. (2019) demonstrated that NDEV p-tau181 discriminates AD from controls with AUC > 0.90\" as key supporting evidence for p-tau231. This is a conflation of distinct phospho-epitopes. Winston et al. (2019, PMID: 31278165) specifically validated **NDEV p-tau181**, not p-tau231. The evidentiary foundation for p-tau231 is considerably weaker than presented—you've borrowed the credibility of one epitope to support another without establishing equivalent evidence.\n\nThe mechanistic claim that p-tau231 \"occurs upstream\" in the tau seeding cascade is also imprecise. Phosphorylation at multiple sites (T181, T217, T231, S396) reflects the activity of overlapping kinase families (GSK-3β, CDK5, DYRK1A) acting in parallel on soluble tau, not a strictly sequential cascade. Regional and cellular context matters enormously.\n\n### Counter-Evidence and Known Complications\n\n1. **Ultrasensitive plasma p-tau assays now perform exceptionally well in preclinical populations.** Janelidze et al. (2020, PMID: 32053791) and Palmqvist et al. (2025) demonstrated plasma p-tau217 AUC > 0.90 for detecting amyloid positivity in cognitively unimpaired individuals. The assumption that plasma assays lack sensitivity in preclinical stages is increasingly obsolete.\n\n2. **L1CAM capture is neither specific nor consistent.** L1CAM (CD171) expression is not exclusive to neurons; it appears on some glial populations, and L1CAM+ isolation captures only a subset of neuron-derived EVs. The bead-based capture introduces substantial inter-individual variability in yield (Kanemoto et al., 2016, PMID: 27588270).\n\n3. **The \"neurodegenerative priming\" concept is vague and potentially unfalsifiable.** If a biomarker fails to show early changes, proponents can always argue that \"priming\" wasn't sufficiently advanced—this framing lacks operational specificity for hypothesis testing.\n\n4. **p-tau231 is elevated in non-AD tauopathies.** Frontotemporal lobar degeneration with MAPT mutations and progressive supranuclear palsy also show elevated p-tau231 in CSF, limiting specificity for AD (Schöll et al., 2017, PMID:",
  "tokens_used": "588"
}